Regulatory & Legal

Peyto's 10-year deal with Centrica links Alberta gas to European prices. It's a masterclass in strategy, but the real story is the invisible journey ahead.

A new lawsuit over atmospheric plasma technology could disrupt supply chains for AI chips and medical devices, highlighting fierce IP battles in high-tech.

Alamos Gold's plan to expand its Manitoba mine raises new questions about balancing economic gains with environmental and Indigenous community impacts.

Largest shareholder Al Shams Investments demands a shareholder meeting, alleging Braemar's board is captive to its advisor amid a high-stakes strategic review.

SOCRadar's 'Best Workplace' award isn't just an HR win. It's the strategic core fueling its AI innovation and rapid growth in a talent-starved industry.

A call for research on vaccine side effects exposes a deeper crisis: the collapse of public trust in science. Can rigorous data heal a polarized nation?

Bluejay Diagnostics secures critical funding to advance its rapid sepsis test, extending its cash runway but raising questions about shareholder dilution.

A press release announced a bright new chapter for DBH. The real story? A $280M debt default, a lender takeover, and a new CEO's daunting mission.

Tinkerine Studios is cleaning house to merge with Fotonara, a tech firm promising data privacy and efficiency. Is this the rebirth of a company or just another RTO gamble?

Nephrodite's implantable dialysis system just entered a key FDA program, signaling a major shift in treating kidney failure. Is freedom from the dialysis chair finally in sight?

A delayed financial report and a plea for a trading halt for its own executives place Premier Health under a harsh spotlight, signaling deeper financial distress.

A burgeoning market for cervical dystonia is set for disruption. A pipeline of novel therapies, including oral options, promises to address unmet patient needs.

An Israeli-American tech firm just put AI eyes on a US Black Hawk, pioneering a new era of visual predictive maintenance that could transform aviation safety.

As AI weaponizes our personal data, your social media is the new frontline. Kanary’s new tools highlight a critical shift in security: protecting people to protect the enterprise.

When an uninsured driver vanishes after a crash, the system can fail victims. A recent case reveals how private investigation is changing the odds.

The FDA just granted Orphan Drug status to a promising ALS therapy. It's a beacon of hope for patients and a masterclass in biotech strategy.

As the old AYR Wellness liquidates, its key assets are reborn under creditor control. A forensic look at the deal, the debt, and what it signals for the industry.

A pivotal trial completes enrollment at a record pace while the AMA lays the groundwork for billing. ShiraTronics is rewriting the medtech playbook.

Nextpower's patent suit against GameChange Energy is more than a legal fight; it's a sign of a maturing industry where intellectual property is the new frontline.

Gene Solutions' SPOT-MAS 10 test gains FDA Breakthrough Designation, accelerating its path to the U.S. market and heralding a new era in early cancer detection.